![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
References
- Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, , Standardisation Sub-committee of the International Continence Society, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourology and Urodynamics 2002; 21: 167–178
- Brown J S, McGhan W F, Chokroverty S. Comorbidities associated with overactive bladder. American Journal of Managed Care 2000; 6: S574–S579
- Cardozo L, Coyne K S, Versi E. Validation of the urgency perception scale. BJU International 2005; 95: 591–596
- Cardozo L, Lisec M, Millard R, Vierssen Trip O V, Kuzmin I, Drogendijk T E, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. Journal of Urology 2004; 172: 1919–1924
- Chapple C R, Artibani W, Cardozo L D, Castro-Diaz D, Craggs M, Haab F, et al. The role of urinary urgency and its measurement in the OAB symptom syndrome: current concepts and future prospects. BJU International 2005; 95: 335–340
- Chapple C R, Gormley E A. Development in pharmacological therapy for the OAB. BJU International S 2006; 1: 78–87
- Chapple C R, Rechberger T, Al-Shukri, Meffan P, Everaert K, Huang M, et al. Randomized, double-blind placebo and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU International 2004; 93: 303–310
- Coyne K S, Tubaro A, Brubaker L, Bavendam T. Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology 2006; 68: S9–S16
- Duggan P. Incontinence. Women's Health, M Finn, L Bowyer, S Carr, V O'Connor, B Vollenhoven. Elsevier Mosby, Sydney 2005; 229–233, A Core Curriculum
- Hashim H, Abrams P. Overactive bladder: an update. Current Opinion in Urology 2007; 17: 231–236
- Kelleher C J, Cardozo L, Chapple C R, Haab F, Ridder A M. Improved quality-of-life in patients with overactive bladder symptoms treated with solifenacin. BJU International 2005; 95: 81–81
- Nabi G, Cody J D, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews 2006; 4: CD003781
- Stewart W F, Herzog A R, Wein A J, Abrams P, Payne C, Corey R, et al. Prevalence and impact of overactive bladder in the United States: Results from the NOBLE program. Neurology and Urodynamics 2001; 20: 403–422
- Stewart W F, Van Rooyen J B, Cundiff G W, Abrams P, Herzog A R, et al. Prevalence and burden of overactive bladder in the United States. World Journal of Urology 2003; 20: 327–326
- Yalcin I, Bump R C. Validation of two global impression questionnaires for incontinence. American Journal of Obstetrics and Gynecology 2003; 189: 98–101